TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00574639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprazolam
Description: 1 mg given orally prior to morning and afternoon clamps on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprazolam
Description: 1 mg given orally prior to morning and afternoon clamps on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 1 mg given orally prior to glucose clamps on Day 1 (morning and afternoon)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 1 mg given orally prior to glucose clamps on Day 1 (morning and afternoon)
Study: NCT04111315

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metamizole Sodium
Description: Novalgin® Oblong tablets 0,5 g 2-2-2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metamizole Sodium
Description: Novalgin® Oblong tablets 0,5 g 2-2-2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 600 mg
Description: Ibufen-L® tablets 500 mg 2-2-2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 600 mg
Description: Ibufen-L® tablets 500 mg 2-2-2

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient education
Description: Leaflet and phone call

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient education
Description: Leaflet and phone call
Study: NCT01951950

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicardipine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esmolol
Study: NCT03878511

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactose
Description: Lactose monohydrate 810 mg, silicon dioxide 20 mg, and magnesium stearate 14 mg

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dextran 40 EP 671 mg, silicon dioxide 20 mg and magnesium stearate 14 mg
Study: NCT02466061

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telemedicine Weight Management plus Wi-Fi Scale (Arm A)
Description: Telephonic weight loss counseling by trained interventionists, with guided digital scale measurements of weight, lean mass, and fat mass. Counseling sessions and digital weight recording occur at regularly scheduled intervals over a six-month intervention period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text for Diet (Text4Diet) Group (Arm B)
Description: Short Message Service (SMS) text messaging in which participants receive 3-5 text messages each day during a six-month intervention period. The text messages provide tips and reminders to encourage healthy eating and weight loss. Participants on this arm also receive a digital scale to track and report weight as prompted once per week through the text program.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care Group (Arm C)
Description: Participants are provided with handouts based on American Cancer Society guidelines for healthy eating and exercise.
Study: NCT03215966

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Macitentan / tadalafil FDC
Description: Tablets for oral administration containing 10 mg of macitentan and 40 mg of tadalafil

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Macitentan / tadalafil FDC
Description: Tablets for oral administration containing 10 mg of macitentan and 40 mg of tadalafil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan (Opsumit®)
Description: Film-coated tablets for oral administration formulated at a strength of 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan (Opsumit®)
Description: Film-coated tablets for oral administration formulated at a strength of 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil (Adcirca®)
Description: Film-coated tablets for oral administration formulated at a strength of 20 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil (Adcirca®)
Description: Film-coated tablets for oral administration formulated at a strength of 20 mg
Study: NCT00625092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Post-operative day 1 and day 2, 600mg/m\^2 intraperitoneal (IP) held for 23 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Day 0 200 mg/m\^2 intraperitoneal held for 2 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Day 0 hyperthermic intraperitoneal oxaliplatin held for 30 minutes - assigned dose level: Levels 1 through 7 - 300 to 600 mg/m\^2

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cytoreductive surgery
Description: Day 0 Cytoreductive surgery is a systematic attempt to remove all or nearly all peritoneal nodules.
Study: NCT01667471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 8 mg/kg iv every 4 weeks, 104 weeks
Study: NCT04161131

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ONBOARD
Description: Session 1: Overview; Overcoming Physical Barriers (experiential wear) Session 2: Managing CGM data (cognitive restructuring) Session 3: Social barriers (problem solving) Session 4: Trust in CGM (motivational interviewing, review of prior sessions)
Study: NCT02834637

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bivalent HPV vaccine
Description: head to head comparisons of different dose schedules and HPV vaccine types

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bivalent HPV vaccine
Description: head to head comparisons of different dose schedules and HPV vaccine types

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bivalent HPV vaccine
Description: head to head comparisons of different dose schedules and HPV vaccine types

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nonavalent HPV vaccine
Description: head to head comparisons of different dose schedules and HPV vaccine types

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nonavalent HPV vaccine
Description: head to head comparisons of different dose schedules and HPV vaccine types

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nonavalent HPV vaccine
Description: head to head comparisons of different dose schedules and HPV vaccine types
Study: NCT00703638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Cisplatin administered intravenously, 75 mg/m\^2 over 1-2 hours on day 1 of a 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed disodium
Description: Pemetrexed 500 mg/m\^2 intravenously (IV) will be given as a 10-minute intravenous infusion (after cisplatin) on day 1 of a 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib
Description: daily oral sorafenib (200 mg or 400 mg bid)
Study: NCT00316563

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marinol (Dronabinol)
Description: Intervention description: Marinol (drug) is being used as an appetite stimulant for treatment of cancer-induced anorexia.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02012478

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MI- informed SMS program
Study: NCT02193958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF-10501-01
Description: FF-10501-01 will be administered orally on Days 1-14 of a 28-day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF-10501-01
Description: FF-10501-01 will be administered orally on Days 1-14 of a 28-day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF-10501-01
Description: FF-10501-01 will be administered orally on Days 1-14 of a 28-day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF-10501-01
Description: FF-10501-01 will be administered orally on Days 1-14 of a 28-day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF-10501-01
Description: FF-10501-01 will be administered orally on Days 1-14 of a 28-day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF-10501-01
Description: FF-10501-01 will be administered orally on Days 1-14 of a 28-day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF-10501-01
Description: FF-10501-01 will be administered orally on Days 1-14 of a 28-day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF-10501-01
Description: FF-10501-01 will be administered orally on Days 1-14 of a 28-day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF-10501-01
Description: FF-10501-01 will be administered orally on Days 1-14 of a 28-day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
Study: NCT00883337

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon β-1a
Description: Sterile preservative-free solution packaged in graduated pre-filled syringes~Subcutaneous injection~Ascending doses from 8.8 to 44 mcg according to local standard for Rebif®

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriflunomide
Description: Film-coated tablet~Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriflunomide
Description: Film-coated tablet~Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriflunomide
Description: Film-coated tablet~Oral administration
Study: NCT01592981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: 1.6 mg/m2 subcutaneous bortezomib on days1, 8 and 15 of 28 days cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide:250 mg/sq m, oral, days 1, 8 and 15 of each cycle in the experimental arm.~Cyclophosphamide:250 mg/sq m, oral, days 1, 2 and 3 of each cycle in the control arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide:250 mg/sq m, oral, days 1, 8 and 15 of each cycle in the experimental arm.~Cyclophosphamide:250 mg/sq m, oral, days 1, 2 and 3 of each cycle in the control arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab: 375 mg/m2 i.v. infusion; days 1, 8, 15 and 22 of cycles 2 and 5 only

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab: 375 mg/m2 i.v. infusion; days 1, 8, 15 and 22 of cycles 2 and 5 only

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine
Description: Fludarabine: 40 mg/sq m, oral, days 1, 2 and 3
Study: NCT03936504

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group ：conventional exercise rehabilitation programs (CERP)
Description: The participants in the control group will receive a conventional exercise rehabilitation programs (CERP) thrice a week for 12 weeks. Each training session lasts for 60 minutes, including ordinary warm-up exercises (10 minutes), aerobic activity (30 minutes), resistive exercise (10 minutes), and cool-down exercises(10 minutes). Each training session includes:(1) an active warm-up including arm-swinging, gentle stretches of the neck, shoulders, spine, arms, legs and so on;(2) aerobic activity mainly including aerobic radio exercise;(3) resistive exercise mainly including elastic belt exercise;(4) cool-down session involving active and static stretching exercises with primary body movements.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental Group ：Tai Chi cardiac rehabilitation program (TCCRP)
Description: Participants perform Tai Chi cardiac rehabilitation program(TCCRP) thrice a week for 12 weeks. Each training session lasts for 60 minutes, including Tai Chi warm-up exercises(10 minutes), Bafa Wubu of Tai Chi(30 minutes), Tai-Chi in conjunction with X-light-band resistance exercise(10 minutes), and Tai Chi cool-down exercises(10 minutes). All participants are encouraged to practice Tai Chi followed the instructional video until finishing 12-week exercise.
Study: NCT02743260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pitavastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pitavastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: digoxin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: digoxin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adefovir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adefovir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin
Study: NCT00763139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: 45 mg by mouth once a day for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: 45 mg by mouth once a day for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: By mouth once a day for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: By mouth once a day for 8 weeks
Study: NCT04135898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIBP-04
Description: 3mg/kg, infusion in 90 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: 3mg/kg, infusion in 90 minutes
Study: NCT01256437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Threolone ointment
Description: ointment once daily for 1 month

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ointment Synthomycine
Description: ointment once daily for 1 month

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ointment Synthomycine
Description: ointment once daily for 1 month

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aqua cream
Description: ointment once daily for 1 month

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aqua cream
Description: ointment once daily for 1 month

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aqua cream
Description: ointment once daily for 1 month
Study: NCT03049904

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vr2L 2Spirit
Description: Three weeks exploring the Vr2L 2Spirit island.~Week 1: Learning Level. Contains the Vr2L 2Spirit island orientation, the learning paths covering HIV testing, harm reduction, safer sex, and condom use \& condom use negotiation, the lodge, the in-world Motivational Interviewing (MI) counseling, and leisure activities.~Week 2: Skills Building Level. The purpose of the city level is for participants to practice the knowledge gained in the Learning level through quests, challenges, and role play scenarios.~Week 3: Experiential Level. Experiential interactions with other participants where they can practice the knowledge and skills they gained in the previous levels.
Study: NCT03726645

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Fecal microbiota transplantation
Description: Fecal microbiota transplantation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fecal microbiota transplantation
Description: Fecal microbiota transplantation
Study: NCT03828279

Intervention type: DIAGNOSTIC_TEST
Intervention: functional and antigenic C1 inhibitor
Description: Diagnosis of HAE is based on personal and/or family history of angioedema and on C1 inhibitor functional or antigenic plasma levels ≤50% of normal.

Intervention type: DIAGNOSTIC_TEST
Intervention: functional and antigenic C1 inhibitor
Description: Diagnosis of HAE is based on personal and/or family history of angioedema and on C1 inhibitor functional or antigenic plasma levels ≤50% of normal.
Study: NCT01146678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine HOE901
Description: Pharmaceutical form:solution for injection~Route of administration: subcutaneous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine HOE901
Description: Pharmaceutical form:solution for injection~Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lixisenatide AVE0010
Description: Pharmaceutical form:solution for injection~Route of administration: subcutaneous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lixisenatide AVE0010
Description: Pharmaceutical form:solution for injection~Route of administration: subcutaneous
Study: NCT01617837

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: P6 acupressure band
Description: Comparison between groups 0-48 hours postoperatively.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo band
Description: Comparison between groups 0-48 hours postoperatively
Study: NCT02200380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDX-301
Description: Related donors will receive CDX-301 for 5 days or 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDX-301 and plerixafor
Description: Related donors will receive CDX-301 for 5 or 7 days plus plerixafor.
Study: NCT01394081

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Engagement and Enrollment (EEE)
Description: Consists of motivational interviewing, educational outreach, and patient navigation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Administrative Outreach (AO)
Description: Consists of giving information about enrolling for VA medical care or scheduling an appointment
Study: NCT02814565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclobenzaprine HCl
Description: Cyclobenzaprine HCl extended-release capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cyclobenzaprine HCl extended release placebo-matching capsules
Study: NCT05815589

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: screw retained prosthesis group
Description: hybrid prosthesis screwed on four mandibular intra-foraminal implants

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: screw retained prosthesis group
Description: hybrid prosthesis screwed on four mandibular intra-foraminal implants
Study: NCT04644809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3561774
Description: Administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3561774
Description: Administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3561774
Description: Administered SC.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC.
Study: NCT04639622

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Investigation procedures
Description: All participants will be assessed longitudinally with a set of clinical evaluation, neuropsychiatric and cognitive assessments, imaging (MRI and PET scans) and biosample (CSF, blood samples)

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Investigation procedures
Description: All participants will be assessed longitudinally with a set of clinical evaluation, neuropsychiatric and cognitive assessments, imaging (MRI and PET scans) and biosample (CSF, blood samples)
Study: NCT04141709

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: local ablative radiotherapy
Description: Within the scope of the study, irradiation with two irradiation schemes is possible (the scheme applied is recorded in the CRF):~* Scheme A 3\*10 Gy (once a day, 2-3 days a week)~* Scheme B 25\*2 Gy (once a day, 5 days a week) The decision which irradiation scheme (3\*10 Gy or 25\*2 Gy) to use is made by the treating physician based on the anatomical position, the size of the metastases and the expected normal tissue load. Hypofractionated irradiation in three fractions is only possible if the limit values for the risk organs are adhered to. Radiotherapy should be performed with photons.
Study: NCT01312597

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fruit juice beverage
Description: 500ml fruit juice beverage, single dose per visit

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fruit juice beverage
Description: 500ml fruit juice beverage, single dose per visit
Study: NCT04230174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11C-PBR28
Description: This study will evaluate, serially, functional and structural tissue changes in the cortex and WM of subjects with RRMS and progressive disease under Ocrelizumab using 11C-PBR28 MR-PET imaging at baseline and at approximately 12-month follow up.
Study: NCT03156400

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Stress Test
Description: Gradual increase in treadmill grade while collecting respiratory gases.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Stress Test
Description: Gradual increase in treadmill grade while collecting respiratory gases.